Syngene anticipates that this move will yield significant benefits for the local economy, including job creation and the stimulation of economic activity, thereby strengthening domestic biologics manufacturing capabilities and contributing to pharmaceutical innovation and supply chain resilience. The company also views this investment as fostering deeper economic collaboration between India and the United States. Peter Bains, CEO Designate of Syngene International, highlighted the strategic rationale, stating that with "one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the USA, we now offer a compelling and flexible solution for global pharma and biotech customers". He added that the investment would enable Syngene to cater to growing client requirements in an expanding market and provide clients with access to the collective service capability of multiple geographic sites.